注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Arrowhead Pharmaceuticals Inc通過沉默導致頑固性疾病的基因來開發治療藥物。該公司使用核糖核酸(RNA)化學和遞送模式的組合,該公司的療法觸發RNA干擾機制,以誘導目標基因的快速、深度和持久的敲低。該公司專注於開發具有遺傳基礎的疾病的藥物,其特徵是一種或多種蛋白質的過度生產。該公司的管線產品包括用於高甘油三酯血症的ARO-APOC3、用於血脂異常的ARO-ANG3、用於囊性纖維化的ARO-ENaC2、用於面肩肱型肌營養不良症的ARO-DUX4、用於導致COVID-19的冠狀病毒和其他可能的未來肺傳播病原體的ARO-COV、用於補體介導疾病的ARO-C3、用於各種粘液阻塞或炎症性肺部疾病的ARO-RAGE和ARO-MUC5AC,以及用於特發性肺纖維化的ARO-MMP7。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Douglass B. Given | 69 | 2010 | Chairman of the Board |
Christopher R. Anzalone | 52 | 2007 | CEO, President & Director |
Robert G. Gish | - | - | Chairman of Hepatitis B Clinical Advisory Board |
William D. Waddill | 65 | 2018 | Independent Director |
Michael S. Perry | 64 | 2011 | Independent Lead Director |
Mauro Ferrari | 64 | 2008 | Independent Director |
Carlo Ferrari | - | - | Member of Hepatitis B Clinical Advisory Board |
Stephen Alister Locarnini | - | - | Member of Hepatitis B Clinical Advisory Board |
Ching-Lung Lai | - | - | Member of Hepatitis B Clinical Advisory Board |
Jeffrey H. Teckman | - | - | Member of Alpha-1 Antitrypsin Deficiency Clinical Advisory Board |
Johnson Y. N. Lau | - | - | Member of Hepatitis B Clinical Advisory Board |
James K. Stoller | - | - | Member of Alpha-1 Antitrypsin Deficiency Clinical Advisory Board |
Rohit Loomba | - | - | Member of Alpha-1 Antitrypsin Deficiency Clinical Advisory Board |
Victoria M. Vakiener | 59 | 2022 | Independent Director |
Adeoye Y. Olukotun | 78 | 2020 | Independent Director |
Mark M. Davis | - | - | Founder and Founder & Director of Insert Therapeutics Inc & Calando |
Hongbo Lu | 52 | 2024 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核